Share this video  

ESMO WCGIC 2020 | Nivolumab for CCA

Richard Kim, MD, of the Moffitt Cancer Center, Tampa, FL, describes Phase II results of nivolumab in patients with advanced, refractory cholangiocarcinoma (CCA). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter